Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.50 (-3.51%)
Spread: 0.50 (3.704%)
Open: 14.25
High: 14.25
Low: 13.75
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

17 May 2006 07:00

Angle PLC17 May 2006 For Immediate Release 17 May 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: Kaloptics, Inc. ANGLE plc ('ANGLE'), the venture management and consulting company specialising in the commercialisation of technology, is pleased to announce that it has signed an agreement with New York University (NYU) to commercialise innovative technology developed at the Media Research Lab in the Computer Science Department of NYU's Courant Institute of Mathematical Sciences. The agreement was effective on 30 April but for reasons of commercial confidentiality was embargoed until now. Researchers Ken Perlin, PhD and Jeff Han have developed a patent-pendingkaleidoscope and software system that enables the rapid capture and recreationof photo-realistic surface images. The technology has a wide range of commercialapplications in multi-billion dollar industries, including special effects,animation, computer gaming and medical devices. As part of its normal model for venture creation, ANGLE has formed and willincubate Kaloptics, Inc. to lead the technology commercialisation, market and IPassessment, and business strategy. ANGLE will contribute the initial managementof Kaloptics and lead a seed financing round for the company. Ken Perlin is a professor in the Department of Computer Science at NYU and wasfounding director of its Media Research Lab. His research interests includegraphics, animation, user interfaces and multimedia. He also received an AcademyAward for Technical Achievement from the Academy of Motion Picture Arts andSciences. Jeff Han, a computer science researcher at NYU, has been working in the fieldsof real-time computer graphics, computer vision, human-computer interfaces andmachine learning for over ten years. ANGLE's Chief Executive, Andrew Newland, said: "We are delighted to be working with New York University and its Media ResearchLab. These are world-class researchers who have produced numerous contributionsto their fields. We believe that the Kaleidoscope system can address a majorissue in multiple markets - the cost effective acquisition of data that can beused for the creation of realistic surface images." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveRob Kornblum, Managing Director US Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About NYU New York University, located in the heart of Greenwich Village, was establishedin 1831 and is one of America's leading research universities and a member ofthe selective Association of American Universities. It is one of the largestprivate universities, it is a leader in attracting international students andscholars in the U.S, and it sends more students to study abroad than any otherU.S. college or university. Through its 14 schools and colleges, NYU conductsresearch and provides education in the arts and sciences, law, medicine,business, dentistry, education, nursing, the cinematic and performing arts,music, public administration, social work, and continuing and professionalstudies, among other areas. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.